Prognostic Role of Elevated Myeloperoxidase in Patients with Acute Coronary Syndrome: A Systemic Review and Meta-Analysis

Table 1

Patients’ characteristics of the studies included in the meta-analysis.

	STEMI (%)	NSTEMI (%)	UAP (%)	MPO cutoff value	Sample size	Age	Female (%)	Smoking (%)	Diabetes (%)	Hypertension (%)
Apple et al. [31]	≥50% of patients have		NA	≤125.6 mcg/L	172		43	NR	24.9	57.9
				>125.6 mcg/L	285
Baldus et al. [34]	0	0	100	<350 μg/L	376		28.7	42.5	8.2	35.4
				≥350 μg/L	171		31	40	12.5	36.9
Brugger-Andersen et al. [30]	AMI 100		0	≤26.8 mcg/L	142		20.8	38.9	10.4	24.4
				>26.8 mcg/L	141
Cavusoglu et al. [38]	12	43	45	≤20.34 ng/mL	91		0.0	32	59	84
				>20.34 ng/mL	91		0.0	43	34	83
Chang et al. [28]	AMI 53.9		NA	<1150 ng/mL	95		10.55	34.7	33.7	60
				≥1150 ng/mL	33		15.1	39.4	51.5	57.6
Eggers et al. [9]	AMI 36.6		21.8	≤208.1 pmol/L	235	66 (55, 76)	33.9	17.2	16.2	37.3
				>208.1 pmol/L	61
Kaya et al. [10]	100	0	0	≤68 ng/mL	37		26	61	20	37
				>68 ng/mL	36		21	66	32	55
Koch et al.^§ [26]	43	NA	NA	≤306.3 pmol/L	396		30.3	32.9	19.2	70.9
				>306.3 pmol/L	267		31.1	33	23.6	67.8
Morrow et al. [39]	0	35	65	≤884 pg/mL	762	61 (52, 69)	32.1	28.7	25.1	67.2
				>884 pg/mL	762	61 (53, 70)	34	29.5	28.9	63.9
Mocatta et al. [27]	81.1	18.9	0	≤55 ng/mL	242		19.9	NA	12.7	NR
				>55 ng/mL	243
Oemrawsingh^† et al. [40]	0	0	100	<350 μg/L	376	62 (54, 69)	20	40	14	42
				≥350 μg/L	171
Rahman et al. [32]	65	30	5	<285.5 pmol/L	30	NR	20	NR	NR	NR
				≥285.5 pmol/L	70
Scirica et al. [29]	0	48.3	49.2	≤670 pg/mL	2507	64	35.1	25	32.3	74.6
				>670 pg/mL	1845

STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; UAP: unstable angina; MPO: myeloperoxidase; CTn1: cardiac troponin I; AMI: acute myocardial infraction; NA: not available. Continuous variables are presented in either median or . Categorical variables are presented in percentages. Apple et al. reported that the median cardiac troponin of the whole cohort is 0.09 μg/L. ^†Oemrawsingh et al. is a longer follow-up report of Baldus et al.’s study subjects. ^§Reported that ACS-negative patients are 10.8% of the study population.